AKT1 and prostate carcinoma: Therefore, the findings indicate that activation of RAS/MAPK signaling serves as a potentiating second hit for alteration of the PTEN/PI3K/AKT axis, and co-targeting both pathways is highly effective in preventing development of metastatic prostate cancers.